Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Regeneus Ltd. ( (AU:CMB) ).
Cambium Bio Limited has announced a change in the address of its registry office in Sydney, effective from April 14, 2025. This move is part of the company’s ongoing operational adjustments and does not affect telephone numbers or postal addresses. The change is expected to streamline operations, potentially impacting stakeholders by improving administrative efficiency.
More about Regeneus Ltd.
Cambium Bio Limited is a Sydney-based clinical-stage regenerative medicine company that develops innovative biologics for ophthalmology and tissue repair applications. The company leverages proprietary technology based on human platelet lysate to create a pipeline of novel therapeutics, focusing primarily on ophthalmology. Its lead product candidate, Elate Ocular®, aims to address unmet medical needs in treating dry eye disease, while its stem cell platform, Progenza™, is used for developing therapies for knee osteoarthritis and other tissue repair indications.
YTD Price Performance: -30.0%
Average Trading Volume: 20,695
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$5.12M
See more data about CMB stock on TipRanks’ Stock Analysis page.